Laura Sanz

Majadahonda, MD 28222, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

GPA33-Targeted Trimeric Immunotoxin Exhibits Enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.

GPA33-Targeted Trimeric Immunotoxin Exhibits Enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.

Journal: International journal of molecular sciences

Published: December 12, 2025

Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies.

Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies.

Journal: Frontiers in immunology

Published: October 31, 2025

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation.

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation.

Journal: Frontiers in immunology

Published: September 10, 2024

Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.

Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.

Journal: Oncoimmunology

Published: April 16, 2024

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.

Journal: Science translational medicine

Published: February 14, 2024

Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates.

Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates.

Journal: Toxicology and applied pharmacology

Published: December 20, 2023

Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.

Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 16, 2023

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.

Journal: Journal of hematology & oncology

Published: June 05, 2023

Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment.

Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment.

Journal: Biomolecules

Published: May 10, 2023

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

Journal: Oncoimmunology

Published: April 28, 2023

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.

Journal: Theranostics

Published: December 03, 2022

Applications of trimerbodies in cancer immunotherapy.

Applications of trimerbodies in cancer immunotherapy.

Journal: International review of cell and molecular biology

Published: July 01, 2022

Showing 1-12 of 47

Last Updated: 09/26/2026